Radiation therapy to treat uterine cancer linked with increased risk of bladder cancer later in life

December 17, 2013

Radiation therapy used to treat uterine cancer may increase a patient's risk of developing bladder cancer. That is the conclusion of a recent study published in BJU International. The findings indicate the importance of monitoring patients for potential signs of bladder cancer to ensure early diagnosis and treatment.

In the United States, uterine cancer is the fourth most common cancer in women, with an estimated 49,560 women diagnosed in 2013. In addition to surgery, 38 percent of patients undergo pelvic radiation therapy to decrease uterine cancer recurrence. Studies have found that women treated with radiation therapy for uterine cancer, like men who received radiation therapy for prostate cancer, have an increased risk of developing bladder cancer later in life.

To investigate the issue, Guan Wu, MD, PhD, of the University of Rochester Medical Center, and his colleagues analyzed the records of 56,681 patients diagnosed with uterine cancer as their first primary malignancy between 1980 and 2005. The information was obtained from the Surveillance, Epidemiology and End-Results (SEER) database.

With an average follow-up of 15 years, bladder cancer incidence in uterine cancer patients treated with pelvic radiation therapy was twice as high as that seen in patients treated without radiation. Similarly, the death rate from bladder cancer was nearly three times higher in patients treated with pelvic radiation than in those who did not receive radiation. It is commonly thought that bladder cancers that develop after pelvic radiation tend to be aggressive, with high grades and stages, but this study found that the types, grades, and stages of bladder cancer that developed were similar in patients treated with and without radiation therapy.

"Physicians who care for patients with a history of uterine cancer and pelvic radiation treatment should keep in mind the increased risk of bladder cancer," said Dr. Wu. "Proper clinical evaluation should be performed to avoid delayed diagnosis, which may improve the quality of care for this group of patients."
-end-


Wiley

Related Bladder Cancer Articles from Brightsurf:

Effectiveness of gemcitabine & daily RT for bladder preservation in muscle-invasive bladder cancer
Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer.

Anthrax may be the next tool in the fight against bladder cancer
Researchers at Purdue University have come up with a way to combine the anthrax toxin with a growth factor to kill bladder cancer cells and tumors.

Effectiveness of a new bladder cancer treatment demonstrated
Demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment.

Lifting the lid on bladder cancer support
Bladder cancer is a painful and sometimes life-threatening condition that patients can find difficult to talk about, with many becoming homebound as they cope with debilitating side effects such as incontinence.

How genomics profiling can help identify the best treatment for bladder cancer
A new computational tool -- a single-patient classifier -- effectively enables physicians to assign a bladder cancer subtype to an individual patient's cancer using that patient's genomic data.

Early menopause in smokers linked to bladder cancer
Research shows that experiencing menopause before the age of 45 is associated with a higher risk of bladder cancer.

Olfactory receptor as therapeutic target in bladder cancer
Researchers from Bochum have detected an olfactory receptor in the human bladder that might prove useful for bladder cancer therapy and diagnosis.

Bladder cancer model could pave the way for better drug efficacy studies
In the journal Cancer Research, UNC Lineberger Comprehensive Cancer Center researchers report they have developed a model of luminal bladder cancer, one of the two subtypes of advanced bladder cancer.

Genetic fixer-uppers may help predict bladder cancer prognosis
Mutations in genes that help repair damage to DNA may aid in predicting the prognosis of patients with bladder and other related cancers, according to researchers, who found that bladder cancer patients who had mutations in their ATM or RB1 genes -- proteins that help repair DNA damage when they're functioning normally -- tended not to live as long as patients without the mutations.

Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer
Researchers from Mount Sinai and Sema4, a health information company and Mount Sinai venture, have discovered that giving metastatic bladder cancer patients simultaneous chemotherapy and immunotherapy is safe and that patients whose tumors have certain genetic mutations may respond particularly well to this combination approach, according to the results of a clinical trial published in European Urology.

Read More: Bladder Cancer News and Bladder Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.